Ligand Pharmaceuticals LGND Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's operating lease right-of-use assets in other assets?
- Ligand Pharmaceuticals (LGND) reported operating lease right-of-use assets in other assets of $6.83M in Q1 2026.
- How has Ligand Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Ligand Pharmaceuticals's operating lease right-of-use assets in other assets decreased by 0.5% year-over-year, from $6.87M to $6.83M.
- What is the long-term trend for Ligand Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a 0.9% compound annual growth rate (CAGR), from $6.89M to $7.22M.